Navigation Links
Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers

- Company Planning to Initiate Phase 2 Trials in Colorectal Cancer and in Hormone-Refractory Prostate Cancer in Q307 -

SOUTH SAN FRANCISCO, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced promising results from an interim safety analysis of two Phase 1 dose-escalating trials of picoplatin, a new generation platinum for the potential first-line treatment of metastatic colorectal cancer (CRC) and metastatic hormone-refractory prostate cancer (HRPC). Initial safety data from the Phase 1 trial in CRC demonstrated that picoplatin can be safely administered with fluorouracil and leucovorin, and initial safety data from the Phase 1 trial in HRPC demonstrated that picoplatin can be safely combined with the dose of docetaxel (Taxotere(R)) used in current practice for HRPC.

The data were included in abstracts published in the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings.

    -- Abstract #14510. Gladkov Jr O, Manikhas G, Biakhov M, Tjulandin S,

       Karlin D. Phase 1 study of picoplatin in combination with 5-

       fluorouracil and leucovorin as initial therapy in subjects with

       metastatic colorectal cancer.

    -- Abstract #15546. Roman L, Karlov P, Kaprin A, Gladkov Jr O, Breitz H.

       Phase 1 study of picoplatin and docetaxel with prednisone in patients

       with chemotherapy-naïve metastatic hormone refractory prostate cancer.


"Our new data indicate that picoplatin can be safely combined with established cancer therapeutics. In 66 patients treated up to 10 months, we have observed reversible myelosuppression that is non-cumulative and has not led to any treatment-related mortality," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "These Phase 1 studies have explored different doses of picoplatin and different dosing schedu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:10/22/2014)... and SHANGHAI , Oct. 22, 2014 ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... offer Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies ... Under the terms of the collaboration, ... the laboratory component of Foundation Medicine,s FoundationOne® assay at ...
(Date:10/20/2014)...  Luoxis Diagnostics, Inc., a subsidiary of Ampio ... its academic collaborators will present several peer-reviewed posters ... novel RedoxSYS Diagnostic System, a first-in-class platform that ... response to injury or illness.  A poster demonstrating ... marker will be presented by Christopher V. ...
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... 22, 2014 Hay House is pleased to ... and Upgrade Your Life (Paperback; $10.82) written by the highly ... Recovery. This book is meant to help readers of ... of recovery. , Recovery 2.0 is not the average ... 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Losing Weight Your ... industry is staring you in the face, it certainly can ... not do your body an extra favor by doing it ... tempting crash diets. Instead, listen to your body, exercise regularly, ... Exercise is essential to losing weight; you need to exercise ...
(Date:10/22/2014)... Reinberg HealthDay Reporter , TUESDAY, ... weight and length may be showing a genetic propensity for ... certain genes have been linked to increased body fat, but ... and lean muscle, the researchers said. At 1 year, ... ages 2 and 3, however, these genes were linked to ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Measures taken ... plantation in Ebola-ravaged Liberia may have limited the spread ... researchers report. The Firestone Natural Rubber Co. provides ... and residents of nearby densely populated communities. Between ... and suspected Ebola cases among those 80,000 people. That ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... Arbor, Mich. Researchers have identified a gene mutation that causes ... according to U-M Medical School scientists. In the study ... Academy of Sciences USA, U-M,s Marci Lesperance, M.D., and ... examined the DNA of individuals from the same large family ...
... LA JOLLA, Calif., July 12, 2010 Some types ... to metastasize than others. Nearly one-third of these aggressive ... known as neuroendocrine-type cells. More rarely, some aggressive prostate ... The presence of neuroendocrine-type cancer cells is associated with ...
... Irvine, Calif., July 12, 2010 UC Irvine public ... research in impoverished reaches of China, Myanmar and Thailand, ... million of a seven-year, $14.5 million award to Pennsylvania ... Infectious Diseases. Yan will collaborate with Penn State principal ...
... A new Mayo Clinic study found that apathy and ... impairment (MCI), a disorder of the brain that affects ... Alzheimer,s disease and Lewy body dementia. The study was ... Honolulu on July 11, 2010. "An important ...
... to be much more complex than previously thought. In ... , Loyola University Health System researchers describe an example of ... be rare in bacteria. This discovery that protein acetylation ... a new age" in bacterial research, senior author Alan Wolfe, ...
... AIDS Society (IAS), conveners of the International AIDS Conference, ... Living with HIV (GNP+), the International Council of AIDS ... HIV/AIDS (ICW) and the United Nations Joint Programme on ... society and local partners for the XIX International AIDS ...
Cached Medicine News:Health News:U-M researchers identify gene mutation that causes rare form of deafness 2Health News:How prostate cancer packs a punch 2Health News:Mayo Clinic study finds apathy and depression predict progression from mild cognitive impairment 2Health News:'Dawning of a new age' in bacteria research 2Health News:Civil society and local partners for XIX International AIDS Conference (AIDS 2012) announced 2Health News:Civil society and local partners for XIX International AIDS Conference (AIDS 2012) announced 3
Esophageal and Anorectal Solid State Catheter Adapter Cable for Polygraf ID...
... of influenza A and B ... to the availability of effective ... influenza using Clearview Exact Influenza ... to reduced hospital stays, antimicrobial ...
... (532 nm) is the newest,addition to ... family is widely,accepted for its reliability, ... it makes,up the worlds largest installed ... OR laser was specifically,designed for the ...
...
Medicine Products: